Guidelines

Psoriasis Workup Expands Beyond Skin: SDPA 2026 Highlights Systemic Risk

Psoriasis management is evolving, with new guidance emphasizing systemic comorbidities beyond dermatological manifestations.

ACOG Simplifies Maternal Immunisation Schedule for GPs

ACOG has streamlined its maternal immunisation schedule, consolidating recommendations to improve adherence and reduce vaccine-preventable diseases in mothers and neonates.

CAR T-Cell Therapy Guidelines Evolve for Lymphoma, Myeloma at EHA 2026

EHA 2026 discussions highlight evolving CAR T-cell therapy guidelines for lymphoma and multiple myeloma, focusing on patient selection and sequencing.

2026 Dyslipidemia Guideline: Utility in Family Medicine Assessed

A new assessment tool, G-TRUST, evaluates the relevance and trustworthiness of cardiovascular risk guidelines, including statin recommendations.

EULAR 2026: Polymyalgia Rheumatica Guidelines Incorporate RWE

EULAR 2026 guidelines for polymyalgia rheumatica (PMR) integrate real-world evidence (RWE), refining diagnostic and treatment algorithms.

PAHO's HEARTS 2.0 Outlines 38-Step Pathway for Cardio-Renal Care

The PAHO HEARTS 2.0 initiative provides a 38-step pathway for integrated cardio-renal care, addressing the complex interplay of cardiovascular and kidney diseases.

ATS 2026: Bronchiectasis and NTM Pulmonary Disease Management

ATS 2026 discussions focused on the complex etiologies and management of bronchiectasis and NTM pulmonary disease, highlighting updated guideline recommendations.

EASL 2026 Consensus: AATD-Liver Disease Management Standardised

A new consensus statement from EASL 2026 aims to standardise the diagnosis and management of Alpha-1 Antitrypsin Deficiency (AATD) related liver disease.

2025 AHA/ACC Hypertension Guidelines: What GPs Need Now

The 2025 AHA/ACC hypertension guidelines update prescribing priorities. Here is what the evidence says about antihypertensive management today.

JAK Inhibitors in RA: 2025 EULAR Safety Update Redraws Risk Guidance

The 2025 EULAR RA update revises JAK inhibitor safety guidance, with implications for prescribing in higher-risk patients.